Melanotan II

What is Melanotan 2?

Melanotan II (Melanotan 2) is a synthetic cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH) and classified as a melanocortin receptor agonist. It was developed as a synthetic melanocortin analogue and is widely studied in research involving melanocortin receptor signaling, receptor interactions, and neuroendocrine pathway investigations. Its cyclic structure provides a defined model for examining melanocortin-system activity in controlled experimental settings.

Unlike more selective melanocortin compounds, Melanotan II has been studied in relation to multiple melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R, making it a commonly used research tool for investigating signaling relationships across the melanocortin system [1].

In scientific literature, Melanotan II has been examined in studies involving:

• Melanocortin receptor signaling and receptor pharmacology

• Pigmentation-related signaling pathways associated with MC1R research

• Neuroendocrine signaling pathways associated with MC3R and MC4R investigations

• Central and peripheral melanocortin-system signaling networks

• Receptor selectivity and multi-receptor pathway interactions

Note that the majority of available data derives from in vitro systems, animal models, and limited early-phase studies.

Multi-Receptor Activity vs. MC1R-Selective Analogues

Melanotan II is frequently compared with other melanocortin compounds in studies examining receptor selectivity, signaling characteristics, and pathway interactions. While some melanocortin analogues, such as Melanotan I, are used primarily in investigations focused on specific receptor subtypes, Melanotan II is commonly utilized in research involving broader melanocortin-system signaling across multiple receptor populations.

This distinction makes Melanotan II a useful research tool for studies designed to investigate relationships between different melanocortin receptors and the signaling pathways associated with their activity.

Bluum Peptides supplies Melanotan II as a high-purity lyophilized research peptide manufactured using industry-standard solid-phase peptide synthesis (SPPS) and purified through high-performance liquid chromatography (HPLC) to achieve purity levels exceeding 99%. All production is conducted in accordance with stringent quality-control procedures and internationally recognized manufacturing standards.

Additionally, each batch undergoes independent third-party analytical verification by laboratories such as Janoshik and BioRegen, with lot-specific Certificates of Analysis (COAs) available to confirm identity, purity, and batch consistency in support of research reproducibility.

Note that all findings referenced here are derived from preclinical and experimental research and should be interpreted strictly within the context of controlled laboratory studies.  For research use only; not intended for human consumption, therapeutic use, diagnostic use, or veterinary applications.

Melanotan II Mechanism of Action (Research Only)

Melanotan II is a synthetic melanocortin receptor agonist studied in research involving melanocortin-system signaling and receptor pharmacology. Experimental studies have examined its interactions with multiple melanocortin receptor subtypes, including MC1R, MC3R, MC4R, and MC5R, making it a commonly used tool for investigating receptor-associated signaling pathways across different biological systems.

Current mechanistic understanding is derived primarily from receptor pharmacology studies, in vitro experiments, and animal models.

Structural and Chemical Basis

Melanotan II is a cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH). Its cyclic structure provides a defined and stable model for investigating melanocortin receptor interactions and signaling processes in experimental systems.

These structural characteristics have made Melanotan II a frequently used research tool in studies examining receptor binding, signaling activity, and pathway relationships within the melanocortin system.

MC1R-Associated Signaling Pathways

Research involving Melanotan II has extensively examined signaling pathways associated with melanocortin receptor 1 (MC1R). Experimental models use this receptor system to investigate melanocortin-mediated cellular signaling and receptor-associated pathway activity.

These studies are commonly employed to explore how melanocortin receptor engagement relates to intracellular communication processes and signaling dynamics within controlled laboratory environments.

MC3R and MC4R Signaling Research

Melanotan II has also been studied in relation to melanocortin receptor subtypes MC3R and MC4R, both of which are frequently investigated in neuroendocrine and central signaling research. Experimental models examine how signaling associated with these receptors relates to broader melanocortin-system activity and pathway interactions.

Because Melanotan II has been studied across multiple receptor populations, it is often used in investigations designed to evaluate relationships between different melanocortin signaling pathways within the same experimental framework.

Multi-Receptor Signaling Activity

One of the defining characteristics of Melanotan II in research settings is its association with multiple melanocortin receptor subtypes. This allows researchers to investigate signaling relationships across interconnected receptor systems rather than focusing exclusively on a single receptor pathway.

As a result, Melanotan II is frequently utilized in studies examining receptor selectivity, signaling integration, pathway crosstalk, and broader melanocortin-system dynamics.

Intracellular Signaling Pathways

Experimental studies have examined Melanotan II in relation to intracellular signaling pathways commonly associated with melanocortin receptor activity, including cyclic AMP (cAMP)-related signaling processes. These investigations are used to evaluate how receptor-associated signaling events relate to downstream cellular communication pathways and broader signaling networks.

Such models provide researchers with a controlled framework for studying melanocortin receptor pharmacology and pathway interactions across multiple biological systems.

Melanotan II is supplied strictly for laboratory research use and serves as a tool for investigating melanocortin receptor signaling and receptor-associated pathway activity. It is not intended for human consumption, therapeutic use, diagnostic use, or veterinary applications.

Melanotan II Mechanism of Action (Research Only)

Melanotan II is a synthetic melanocortin receptor agonist studied in research involving melanocortin-system signaling and receptor pharmacology, making it a widely used tool for investigating receptor-associated signaling pathways across both peripheral and central experimental models.

Current mechanistic understanding is derived primarily from receptor pharmacology studies, in vitro experiments, and animal models.

Structural and Chemical Basis

Melanotan II is a cyclic heptapeptide derived from α-melanocyte-stimulating hormone (α-MSH). Its cyclic structure provides a stable and well-characterized model for studying melanocortin receptor interactions and receptor-mediated signaling processes in controlled experimental systems.

These structural characteristics have contributed to its widespread use in studies examining receptor binding, signaling activity, receptor selectivity, and pathway interactions within the melanocortin system.

Melanocortin Receptor Signaling

A distinguishing feature of Melanotan II is its association with multiple melanocortin receptor subtypes. Unlike more selective melanocortin compounds, it has been studied in relation to MC1R, MC3R, MC4R, and MC5R signaling, allowing researchers to investigate receptor-specific and multi-receptor signaling activity within a single experimental framework.

This broad receptor profile makes Melanotan II particularly useful for studying how signaling pathways associated with different melanocortin receptors interact across complex biological systems.

MC1R-Associated Pathways

Research involving Melanotan II has extensively examined signaling pathways associated with melanocortin receptor 1 (MC1R). Experimental models use this receptor system to investigate melanocortin-mediated cellular signaling, receptor activation, and downstream pathway activity within controlled laboratory environments.

These studies contribute to a broader understanding of melanocortin receptor pharmacology and receptor-associated signaling dynamics.

MC3R and MC4R Signaling Research

Melanotan II has also been studied in relation to MC3R- and MC4R-associated signaling pathways, both of which are frequently investigated in neuroendocrine and central signaling research. Experimental models examine how signaling linked to these receptors relates to broader melanocortin-system activity and pathway interactions.

Researchers use these systems to investigate relationships among receptor activity, signaling coordination, and interconnected melanocortin pathways under controlled experimental conditions.

Intracellular Signaling and cAMP Pathways

Experimental studies have examined Melanotan II in relation to intracellular signaling pathways commonly associated with melanocortin receptor activity, including cyclic AMP (cAMP)-related signaling processes. These investigations are used to evaluate how receptor-associated signaling events correspond with downstream cellular communication pathways and broader signaling networks.

Such models provide a framework for studying melanocortin receptor pharmacology, signal transduction, and pathway relationships across multiple biological systems.

Melanotan II is supplied strictly for laboratory research use and serves as a tool for investigating melanocortin receptor signaling, receptor pharmacology, and pathway interactions. It is not intended for human consumption, therapeutic use, diagnostic use, or veterinary applications.

Melanotan II vs Melanotan I vs α-MSH vs Bremelanotide

Melanotan II is commonly compared with other melanocortin peptides to understand differences in receptor selectivity and signaling scope.

This comparison helps frame Melanotan 2 within the broader melanocortin landscape, especially against more selective analogues like Melanotan I, endogenous ligands like α-MSH, and centrally active compounds such as bremelanotide.

Melanotan II stands out primarily because of its breadth. Where Melanotan I is typically chosen for controlled pigmentation studies and α-MSH for baseline physiological comparisons, Melanotan II is used when the goal is to observe how multiple melanocortin pathways interact in the same system. That makes it particularly useful in experiments where receptor cross-talk, signaling overlap, or system-level responses are part of the research question.

At the same time, that broader activity comes with tradeoffs. Because it engages multiple receptors, Melanotan II introduces more variables into experimental design, which can make interpretation less straightforward compared to more selective ligands. For that reason, it is often used alongside more targeted compounds rather than as a direct substitute.

Melanotan II supplied by Bluum Peptides is a research compound intended strictly for laboratory use. It is not approved for human or veterinary applications and should be clearly distinguished from clinically developed melanocortin agents in both procurement and study design.

Melanotan II Laboratory Safety & Handling (Research Use Only)

Melanotan II is a synthetic cyclic melanocortin peptide supplied as a lyophilized research material. As with other biologically active research compounds, it should be handled in accordance with established laboratory practices and institutional safety protocols. Proper handling and storage are important for maintaining material integrity and supporting consistency across experimental workflows.

Due to its peptide structure, Melanotan II may be affected by environmental factors such as moisture, temperature fluctuations, excessive light exposure, and repeated handling. These factors can introduce variability into research applications and should be carefully controlled within laboratory environments.

Laboratory Handling Considerations

Melanotan II should be handled using standard laboratory procedures appropriate for lyophilized peptide materials.

• Follow institutional standard operating procedures (SOPs), chemical hygiene plans, and approved research protocols

• Wear appropriate personal protective equipment (PPE), including gloves, laboratory coat, and eye protection

• Perform weighing and handling procedures in controlled laboratory environments where appropriate to minimize contamination and environmental exposure

• Handle powders carefully to reduce airborne particulates and avoid contact with skin, eyes, and mucous membranes

• Utilize suitable laboratory containers and equipment to support sample integrity during handling and storage

• Maintain accurate records of lot numbers, preparation dates, and related research documentation to support traceability and reproducibility

These practices help support consistency across receptor-signaling and melanocortin-system research applications.

Storage and Stability Considerations

Proper storage conditions are important for maintaining the integrity of lyophilized peptide materials during research use.

• Store material according to product documentation and laboratory protocols

• Protect from excessive heat, light, moisture, and unnecessary environmental stress during storage and handling

• Minimize repeated freeze–thaw exposure and other conditions that may affect material integrity

• Maintain consistent storage conditions across experiments to support reproducibility

• Inspect materials and documentation prior to use as part of routine laboratory quality-control procedures

Appropriate storage and handling practices help support consistency across experimental workflows and reduce avoidable sources of variability in research environments.

Melanotan II is supplied strictly for research use only. Bluum Peptides does not provide or imply medical, diagnostic, or therapeutic guidance regarding this compound. This material is not intended for human consumption, veterinary use, diagnosis, treatment, or therapeutic application and must be handled exclusively within qualified laboratory settings.

Certificate of Analysis (COA) & Quality Assurance

Each lot of Melanotan II is accompanied by a third-party-verified Certificate of Analysis (COA), providing batch-specific confirmation of identity and purity to support reproducibility and data integrity in laboratory research. Bluum Peptides partners with leading independent analytical laboratories, such as Janoshik Analytical and BioRegen, to verify peptide identity, purity, and composition, ensuring consistent quality and reliable performance across research batches.

This is particularly important for multi-receptor melanocortin peptides, where even small variations in composition can influence receptor binding profiles and downstream signaling behavior.

COAs typically include:

●       Identity verification using analytical techniques such as mass spectrometry or equivalent peptide-confirmation methods

●       Purity assessment, commonly determined by high-performance liquid chromatography (HPLC) or comparable chromatographic analysis

●       Relevant physicochemical characteristics, such as appearance and solubility profile where applicable

●       Lot number, date of analysis, and detailed analytical methodology to support traceability and reproducibility

Third-party testing by independent analytical laboratories ensures objective verification of peptide identity and purity, reinforcing consistent quality standards across production batches.

Certificates of Analysis are available for review on the product page, and researchers are encouraged to retain COAs as well as internal documentation for validation, audit requirements, and reproducibility tracking in accordance with institutional and laboratory protocols.

Scientific References

1. Cai M, Hruby VJ, The Melanocortin Receptor System: A Target for Multiple Degenerative Diseases, Current Protein and Peptide Science, 2016;17(5):488–496, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5999398/

2. Yeo GSH, Chao DHM, Siegert AM, Koerperich ZM, Ericson MD, Simonds SE, Larson CM, Luquet S, Clarke I, Sharma S, Clément K, Cowley MA, Haskell-Luevano C, Van Der Ploeg L, Adan RAH, The melanocortin pathway and energy homeostasis: From discovery to obesity therapy, Molecular Metabolism, 2021 Jun;48:101206, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8050006/

3. Böhm M, Robert C, Malhotra S, Clément K, Farooqi S, An overview of benefits and risks of chronic melanocortin-1 receptor activation, Journal of the European Academy of Dermatology and Venereology, 2025 Jan;39(1):39–51, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11664455/

4. Micioni Di Bonaventura E, Botticelli L, Tomassoni D, Tayebati SK, Micioni Di Bonaventura MV, Cifani C, The Melanocortin System behind the Dysfunctional Eating Behaviors, Nutrients, 2020 Nov 14;12(11):3502, https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7696960/